Старение, медицина, биотехнологии — Ивар ft. Петр Федичев | Мыслить как ученый #44

Scientific concepts, discoveries, and phenomena mentioned

Aging as a “complex system” and an economic/social problem

• Aging is discussed not only as biology, but as an emergent property of society (demographic transition), affecting:
  • pensions
  • healthcare systems
  • workforce productivity
• The speaker argues that modern medicine extends life, so more people reach late-life phases characterized by functional impairment rather than only terminal disease.

Functional impairment (not just disease) and “health span”

Aging is framed primarily as:

• decreased body functions (physical limitations)
• decreased cognitive/problem-solving abilities

This leads to reduced quality of life and productivity even without classic dementia diagnoses.

Two related but distinct targets are emphasized:

• Healthspan: lifespan in which one remains functional/“cool” and productive, with or without disease.
• “Lifespan” / duration of life: maximizing time alive regardless of function.

Claim: different interventions may be needed depending on whether the goal is healthspan vs. maximal longevity.

Cultural/social drivers affecting medicine adoption

Societal attitudes influence what gets developed and adopted:

• Preventive use of drugs is perceived as “unnatural/chemical,” so people resist taking medication until they are “really bad.”
• End-of-life norms and healthcare policy (e.g., whether euthanasia is permitted) are mentioned as cultural factors affecting how long people are kept alive.

Mortality “doubling” with age and risk accumulation

• A key quantitative claim is that risk of illness/death doubles approximately every 8 years (geometric progression of age-related mortality).
• Related implication: interventions that reduce risk by some percentage may translate to limited gains in maximum lifespan unless they target core aging mechanisms.

Antibiotics/statins and longer survival → later-stage burdens

• Antibiotics/statins are described as increasing survival to ages where chronic conditions (including cancer) become common.
• Cancer ten-year survival is cited as ~50% (as stated).
• “Trap” described: people live longer, but accumulate late-life functional decline.

“No 120–130–150 years” and the proposed maximum-longevity limitation

A major focus is why very few (or no) people live beyond ~120–130 years, despite growing populations.

The talk claims this is not merely a disease story, but is tied to loss of:

• “resilience/stability”—the ability of physiological systems to recover from stressors.

Recovery time / hospital stay as an aging signal

Observed pattern:

• time to recovery after difficult events (e.g., death of relatives, infection/injury, surgery/hospital stay) increases with age
• hospital stay vs. age is claimed to accelerate faster than linear
• extrapolation suggests that near extreme ages (~120), recovery time could become “endless”

This is connected to the idea of dynamic systems losing stability with age.

COVID-19 used as an example of age-linked loss of control

• Older age is stated to lead to longer time for immune responses to start and stop, contributing to uncontrolled outcomes (e.g., sepsis-like dynamics).

“Resilience/Resilins” and maximum lifespan as a biophysical mechanism

• The discussion uses “resilience / stability” (auto-transcribed; “reslins/resilins” appears) as a core mechanism limiting maximum lifespan.
• Claim: improving stability could increase maximum longevity without necessarily treating specific diseases.

Engineering approach to longevity drugs

The claim is that in ~10 years researchers:

• identified measurable biological systems associated with:
  • average life expectancy
  • maximum longevity
  • specific diseases

Therefore drug development might diverge into:

• drugs that increase average lifespan
• drugs that increase maximum longevity
• drugs that target specific diseases

GLP-1 agonists (example of multi-disease risk reduction)

Semaglutide (Ozempic/Ozempic) and similar drugs are discussed as examples where:

• initial development was for diabetes/weight loss
• regulatory classification and societal framing changed market opportunity
• clinical studies showed reductions in risk not only for diabetes/obesity, but for many other diseases

Quantitative claim (as stated):

• risks of “more than ten diseases” reduced by ~30%

Caveat from the talk:

• translating risk reduction into lifespan gain may still be small (on the order of ~1 year) given age-risk doubling dynamics.

Regulatory barriers limiting true anti-aging development

The talk argues:

• regulatory and investment incentives require studying drugs against existing diseases
• this produces “weak” anti-aging candidates because they are tied to disease endpoints

Proposed fix:

• develop interventions aimed directly at aging mechanisms, not only at disease treatment.

---

Methodology / framework described

• Define aging targets separately
  • maximize healthspan (functional/productive time)
  • maximize lifespan
  • potentially separate interventions for average life expectancy vs maximum longevity
• Identify measurable aging-linked parameters
  • recovery/stability dynamics (e.g., age-dependent recovery time; hospital stay duration vs age)
  • dynamic-system “loss of stability” concept
• Use engineering principles
  • measure biological/physiological systems
  • treat them as controllable components (bioengineering drug development)
  • aim to shift stability limits that constrain maximal lifespan
• Understand incentives and regulation
  • study how society/culture and regulators prioritize disease treatment
  • note that without endpoints connected to aging, investors/regulators avoid “pure anti-aging” trials
• Look for candidate drugs that show broad risk effects
  • example given: GLP-1 agonists reducing risk across multiple disease categories

---

Researchers/sources mentioned (as requested)

• Ivar (Ivor) Maksutov (podcast host; Postnauka founder)
• Пётр Федичев (Петр Федичев / Pyotr Fedichev) (associate professor; guest; founder/biotech context in transcript)
• David Sinclair
• Aubrey de Grey
• Sergey Pavlovich Korolev (mentioned as an example in an aside; not aging research)
• Allan Musk (mentioned in the context of Elon Musk / Rogan; name appears distorted in auto-subtitles)
• Elon Musk
• Sam Altman
• Jeff Bezos
• Mark Andreessen / Marc Andreessen (auto-transcribed variants; presented as Mark Andreessen)
• OpenAI / Ilya Sutskever (Ilya mentioned)
• AGI / AG1 (mentioned; not a specific scientific researcher)
• World Health Organization (WHO) (as a regulatory/policy shift source)
• International Monetary Fund (IMF)
• Rothschild (mentioned as an investor/business partner connected to early actuarial work; surname appears via text)
• Christopher/Chris Prkas / “Chris Prkas” (auto-transcribed; intended reference unclear)
• Brian Johnson (personal longevity experimentation; mentioned as “Blueprint”)
• Misha Batin (mentioned as a popularizer related to anti-aging)
• Misha (also “Misha Batin’s fantasies” in transcript)
• Moscow State University / Moscow (as a research location; not a person)
• IVI / Invitro (company mentioned; spelling unclear)
• Novo Nordisk (spelled in transcript as Novonordisk; GLP-1 context)
• Lilly (Eli Lilly; GLP-1/pharma context)
• AstroZeneca (spelled “Astrozeneca” in transcript; Postnauka cycle mention)
• Rogан (The Joe Rogan Podcast) (source/venue mentioned)
• Postnauka (media organization; not a researcher but repeatedly referenced)
• Think Like a Scientist (podcast name; source/venue mentioned)

Note: Some personal names are likely distorted by auto-generated subtitles. Where intended identity is ambiguous, it’s reflected implicitly by transcript spelling.